Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2016

View Archived Issues

Mutations in ZAS may be associated with congenital myopathy

Mersana's XMT-1536 targets tumors expressing sodium-dependent phosphate transport protein 2B

TRIP-13 identified as a therapeutic target in hepatocellular carcinoma

Vasohibin-1 shows promise as a therapeutic target for diabetic erectile dysfunction

Ionis and MD Anderson form strategic alliance to discover and develop novel cancer therapeutics

Darzalex receives European conditional marketing authorization for multiple myeloma

Positive topline results from a first-in-human trial of broad spectrum MVA-BN RSV vaccine

Catabasis' SREBP inhibitors show potential for NASH

Merck & Co. patent orexin receptor antagonists

ETHZ, Roche and Universität Zürich disclose CB2 receptor ligands

ECUST and SIMM report dipeptidyl peptidase IV inhibitors

Enanta Pharmaceuticals discloses farnesoid X receptor agonists

IOmet Pharma divulges indoleamine and tryptophan dioxygenase inhibitors

Bayer Schering Pharma announces t-PA inhibitors

New studies support utility of GastroPanel to predict stomach cancer risk

Advanced Accelerator Applications scales up Lutathera production

Survival benefit with Pentaglobin in severe infections caused by multidrug-resistant bacteria

Onoclys BioPharma announces licensing developments

FDA awards fast track designation for AEB-1102 in hyperargininemia

Boehringer Ingelheim and Biomed X establish a global research team

Avastin approved in Japan for cervical cancer

Phase III trial results presented for alirocumab in Japan

Alimera reports real world data on Iluvien in patients with DME

Exelixis reports phase II results for cabozantinib

Interim phase II data for bardoxolone methyl show improvement in renal function

Arbor Pharmaceuticals set to acquire XenoPort

ZVex/mIL12 shows promising antitumor effect in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...